The global Enzalutamide Soft Capsules market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Enzalutamide soft capsules are an oral medication used in the treatment of metastatic castration-resistant prostate cancer. Each soft capsule contains the active ingredient enzalutamide, a potent androgen receptor inhibitor that works by inhibiting the action of androgens (such as testosterone) on prostate cancer cells.

From a downstream perspective, Hospital and Clinic accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Enzalutamide Soft Capsules leading manufacturers including Astellas Pharma, Pfizer, Intas Pharmaceuticals, Aprazer Healthcare Pharma, Arechar Healthcare, Glenmark Pharma, BDR Pharma, Qilu Pharmaceutical, Kelun Pharmaceutical, Yichang Humanwell Pharmaceutical, etc., dominate supply; the top five capture approximately % of global revenue, with Astellas Pharma leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Enzalutamide Soft Capsules market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Enzalutamide Soft Capsules Market Report

Report Metric	Details
Report Name	Enzalutamide Soft Capsules Market
Segment by Type	Original Drug Generic Drug
Segment by Application	Hospital and Clinic Retail Pharmacies Other
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Astellas Pharma, Pfizer, Intas Pharmaceuticals, Aprazer Healthcare Pharma, Arechar Healthcare, Glenmark Pharma, BDR Pharma, Qilu Pharmaceutical, Kelun Pharmaceutical, Yichang Humanwell Pharmaceutical, Jiangsu Hansoh Pharmaceutical, PuraCap Pharmaceuticals, Shenyang Hongqi Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Enzalutamide Soft Capsules study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Enzalutamide Soft Capsules Market report?

Ans: The main players in the Enzalutamide Soft Capsules Market are Astellas Pharma, Pfizer, Intas Pharmaceuticals, Aprazer Healthcare Pharma, Arechar Healthcare, Glenmark Pharma, BDR Pharma, Qilu Pharmaceutical, Kelun Pharmaceutical, Yichang Humanwell Pharmaceutical, Jiangsu Hansoh Pharmaceutical, PuraCap Pharmaceuticals, Shenyang Hongqi Pharmaceutical

What are the Application segmentation covered in the Enzalutamide Soft Capsules Market report?

Ans: The Applications covered in the Enzalutamide Soft Capsules Market report are Hospital and Clinic, Retail Pharmacies, Other

What are the Type segmentation covered in the Enzalutamide Soft Capsules Market report?

Ans: The Types covered in the Enzalutamide Soft Capsules Market report are Original Drug, Generic Drug

1 Study Coverage

1.1 Introduction to Enzalutamide Soft Capsules: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Enzalutamide Soft Capsules Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Original Drug

1.2.3 Generic Drug

1.3 Market Segmentation by Application

1.3.1 Global Enzalutamide Soft Capsules Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Hospital and Clinic

1.3.3 Retail Pharmacies

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Enzalutamide Soft Capsules Revenue Estimates and Forecasts 2020-2031

2.2 Global Enzalutamide Soft Capsules Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Enzalutamide Soft Capsules Sales Estimates and Forecasts 2020-2031

2.4 Global Enzalutamide Soft Capsules Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global Enzalutamide Soft Capsules Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global Enzalutamide Soft Capsules Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 Original Drug Market Size by Manufacturers

3.5.2 Generic Drug Market Size by Manufacturers

3.6 Global Enzalutamide Soft Capsules Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Enzalutamide Soft Capsules Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global Enzalutamide Soft Capsules Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Enzalutamide Soft Capsules Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global Enzalutamide Soft Capsules Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America Enzalutamide Soft Capsules Sales and Revenue by Type (2020-2031)

6.4 North America Enzalutamide Soft Capsules Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Enzalutamide Soft Capsules Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe Enzalutamide Soft Capsules Sales and Revenue by Type (2020-2031)

7.4 Europe Enzalutamide Soft Capsules Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Enzalutamide Soft Capsules Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific Enzalutamide Soft Capsules Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific Enzalutamide Soft Capsules Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific Enzalutamide Soft Capsules Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America Enzalutamide Soft Capsules Sales and Revenue by Type (2020-2031)

9.4 Central and South America Enzalutamide Soft Capsules Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Enzalutamide Soft Capsules Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa Enzalutamide Soft Capsules Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa Enzalutamide Soft Capsules Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Enzalutamide Soft Capsules Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Astellas Pharma

11.1.1 Astellas Pharma Corporation Information

11.1.2 Astellas Pharma Business Overview

11.1.3 Astellas Pharma Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.1.4 Astellas Pharma Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Astellas Pharma Enzalutamide Soft Capsules Sales by Product in 2024

11.1.6 Astellas Pharma Enzalutamide Soft Capsules Sales by Application in 2024

11.1.7 Astellas Pharma Enzalutamide Soft Capsules Sales by Geographic Area in 2024

11.1.8 Astellas Pharma Enzalutamide Soft Capsules SWOT Analysis

11.1.9 Astellas Pharma Recent Developments

11.2 Pfizer

11.2.1 Pfizer Corporation Information

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.2.4 Pfizer Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 Pfizer Enzalutamide Soft Capsules Sales by Product in 2024

11.2.6 Pfizer Enzalutamide Soft Capsules Sales by Application in 2024

11.2.7 Pfizer Enzalutamide Soft Capsules Sales by Geographic Area in 2024

11.2.8 Pfizer Enzalutamide Soft Capsules SWOT Analysis

11.2.9 Pfizer Recent Developments

11.3 Intas Pharmaceuticals

11.3.1 Intas Pharmaceuticals Corporation Information

11.3.2 Intas Pharmaceuticals Business Overview

11.3.3 Intas Pharmaceuticals Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.3.4 Intas Pharmaceuticals Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 Intas Pharmaceuticals Enzalutamide Soft Capsules Sales by Product in 2024

11.3.6 Intas Pharmaceuticals Enzalutamide Soft Capsules Sales by Application in 2024

11.3.7 Intas Pharmaceuticals Enzalutamide Soft Capsules Sales by Geographic Area in 2024

11.3.8 Intas Pharmaceuticals Enzalutamide Soft Capsules SWOT Analysis

11.3.9 Intas Pharmaceuticals Recent Developments

11.4 Aprazer Healthcare Pharma

11.4.1 Aprazer Healthcare Pharma Corporation Information

11.4.2 Aprazer Healthcare Pharma Business Overview

11.4.3 Aprazer Healthcare Pharma Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.4.4 Aprazer Healthcare Pharma Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 Aprazer Healthcare Pharma Enzalutamide Soft Capsules Sales by Product in 2024

11.4.6 Aprazer Healthcare Pharma Enzalutamide Soft Capsules Sales by Application in 2024

11.4.7 Aprazer Healthcare Pharma Enzalutamide Soft Capsules Sales by Geographic Area in 2024

11.4.8 Aprazer Healthcare Pharma Enzalutamide Soft Capsules SWOT Analysis

11.4.9 Aprazer Healthcare Pharma Recent Developments

11.5 Arechar Healthcare

11.5.1 Arechar Healthcare Corporation Information

11.5.2 Arechar Healthcare Business Overview

11.5.3 Arechar Healthcare Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.5.4 Arechar Healthcare Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 Arechar Healthcare Enzalutamide Soft Capsules Sales by Product in 2024

11.5.6 Arechar Healthcare Enzalutamide Soft Capsules Sales by Application in 2024

11.5.7 Arechar Healthcare Enzalutamide Soft Capsules Sales by Geographic Area in 2024

11.5.8 Arechar Healthcare Enzalutamide Soft Capsules SWOT Analysis

11.5.9 Arechar Healthcare Recent Developments

11.6 Glenmark Pharma

11.6.1 Glenmark Pharma Corporation Information

11.6.2 Glenmark Pharma Business Overview

11.6.3 Glenmark Pharma Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.6.4 Glenmark Pharma Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 Glenmark Pharma Recent Developments

11.7 BDR Pharma

11.7.1 BDR Pharma Corporation Information

11.7.2 BDR Pharma Business Overview

11.7.3 BDR Pharma Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.7.4 BDR Pharma Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 BDR Pharma Recent Developments

11.8 Qilu Pharmaceutical

11.8.1 Qilu Pharmaceutical Corporation Information

11.8.2 Qilu Pharmaceutical Business Overview

11.8.3 Qilu Pharmaceutical Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.8.4 Qilu Pharmaceutical Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.8.5 Qilu Pharmaceutical Recent Developments

11.9 Kelun Pharmaceutical

11.9.1 Kelun Pharmaceutical Corporation Information

11.9.2 Kelun Pharmaceutical Business Overview

11.9.3 Kelun Pharmaceutical Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.9.4 Kelun Pharmaceutical Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.9.5 Kelun Pharmaceutical Recent Developments

11.10 Yichang Humanwell Pharmaceutical

11.10.1 Yichang Humanwell Pharmaceutical Corporation Information

11.10.2 Yichang Humanwell Pharmaceutical Business Overview

11.10.3 Yichang Humanwell Pharmaceutical Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.10.4 Yichang Humanwell Pharmaceutical Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.10.5 Yichang Humanwell Pharmaceutical Recent Developments

11.11 Jiangsu Hansoh Pharmaceutical

11.11.1 Jiangsu Hansoh Pharmaceutical Corporation Information

11.11.2 Jiangsu Hansoh Pharmaceutical Business Overview

11.11.3 Jiangsu Hansoh Pharmaceutical Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.11.4 Jiangsu Hansoh Pharmaceutical Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.11.5 Jiangsu Hansoh Pharmaceutical Recent Developments

11.12 PuraCap Pharmaceuticals

11.12.1 PuraCap Pharmaceuticals Corporation Information

11.12.2 PuraCap Pharmaceuticals Business Overview

11.12.3 PuraCap Pharmaceuticals Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.12.4 PuraCap Pharmaceuticals Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.12.5 PuraCap Pharmaceuticals Recent Developments

11.13 Shenyang Hongqi Pharmaceutical

11.13.1 Shenyang Hongqi Pharmaceutical Corporation Information

11.13.2 Shenyang Hongqi Pharmaceutical Business Overview

11.13.3 Shenyang Hongqi Pharmaceutical Enzalutamide Soft Capsules Product Models, Descriptions and Specifications

11.13.4 Shenyang Hongqi Pharmaceutical Enzalutamide Soft Capsules Sales, Price, Revenue and Gross Margin (2020-2025)

11.13.5 Shenyang Hongqi Pharmaceutical Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 Enzalutamide Soft Capsules Industry Chain

12.2 Enzalutamide Soft Capsules Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 Enzalutamide Soft Capsules Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 Enzalutamide Soft Capsules Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Enzalutamide Soft Capsules Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Enzalutamide Soft Capsules Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Astellas Pharma

Pfizer Inc

Intas Pharmaceuticals

Aprazer Healthcare Pharma

Yichang Humanwell Pharmaceutical

Jiangsu Hansoh Pharmaceutical

Puracap Pharmaceuticals

Shenyang Hongqi Pharmaceutical

List of Tables

Table 1. Global Enzalutamide Soft Capsules Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Enzalutamide Soft Capsules Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Enzalutamide Soft Capsules Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Enzalutamide Soft Capsules Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Enzalutamide Soft Capsules Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Enzalutamide Soft Capsules Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)

Table 7. Global Enzalutamide Soft Capsules Sales by Region (2020-2025) & (K Units)

Table 8. Global Enzalutamide Soft Capsules Sales by Region (2026-2031) & (K Units)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Enzalutamide Soft Capsules Sales by Manufacturers (2020-2025) & (K Units)

Table 11. Global Enzalutamide Soft Capsules Sales Share by Manufacturers (2020-2025)

Table 12. Global Enzalutamide Soft Capsules Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global Enzalutamide Soft Capsules Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global Enzalutamide Soft Capsules by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Enzalutamide Soft Capsules as of 2024)

Table 16. Global Enzalutamide Soft Capsules Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global Enzalutamide Soft Capsules Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)

Table 18. Key Manufacturers Enzalutamide Soft Capsules Manufacturing Base and Headquarters

Table 19. Global Enzalutamide Soft Capsules Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global Enzalutamide Soft Capsules Sales by Type (2020-2025) & (K Units)

Table 23. Global Enzalutamide Soft Capsules Sales by Type (2026-2031) & (K Units)

Table 24. Global Enzalutamide Soft Capsules Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global Enzalutamide Soft Capsules Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global Enzalutamide Soft Capsules ASP by Type (2020-2031) & (US$/Unit)

Table 27. Technical Specifications by Key Product Type

Table 28. Global Enzalutamide Soft Capsules Sales by Application (2020-2025) & (K Units)

Table 29. Global Enzalutamide Soft Capsules Sales by Application (2026-2031) & (K Units)

Table 30. Enzalutamide Soft Capsules High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global Enzalutamide Soft Capsules Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global Enzalutamide Soft Capsules Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global Enzalutamide Soft Capsules ASP by Application (2020-2031) & (US$/Unit)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America Enzalutamide Soft Capsules Growth Accelerators and Market Barriers

Table 37. North America Enzalutamide Soft Capsules Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America Enzalutamide Soft Capsules Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 39. Europe Enzalutamide Soft Capsules Growth Accelerators and Market Barriers

Table 40. Europe Enzalutamide Soft Capsules Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe Enzalutamide Soft Capsules Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific Enzalutamide Soft Capsules Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific Enzalutamide Soft Capsules Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific Enzalutamide Soft Capsules Growth Accelerators and Market Barriers

Table 45. Southeast Asia Enzalutamide Soft Capsules Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America Enzalutamide Soft Capsules Investment Opportunities and Key Challenges

Table 47. Central and South America Enzalutamide Soft Capsules Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa Enzalutamide Soft Capsules Investment Opportunities and Key Challenges

Table 49. Middle East and Africa Enzalutamide Soft Capsules Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Astellas Pharma Corporation Information

Table 51. Astellas Pharma Description and Major Businesses

Table 52. Astellas Pharma Product Models, Descriptions and Specifications

Table 53. Astellas Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 54. Astellas Pharma Sales Value Proportion by Product in 2024

Table 55. Astellas Pharma Sales Value Proportion by Application in 2024

Table 56. Astellas Pharma Sales Value Proportion by Geographic Area in 2024

Table 57. Astellas Pharma Enzalutamide Soft Capsules SWOT Analysis

Table 58. Astellas Pharma Recent Developments

Table 59. Pfizer Corporation Information

Table 60. Pfizer Description and Major Businesses

Table 61. Pfizer Product Models, Descriptions and Specifications

Table 62. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 63. Pfizer Sales Value Proportion by Product in 2024

Table 64. Pfizer Sales Value Proportion by Application in 2024

Table 65. Pfizer Sales Value Proportion by Geographic Area in 2024

Table 66. Pfizer Enzalutamide Soft Capsules SWOT Analysis

Table 67. Pfizer Recent Developments

Table 68. Intas Pharmaceuticals Corporation Information

Table 69. Intas Pharmaceuticals Description and Major Businesses

Table 70. Intas Pharmaceuticals Product Models, Descriptions and Specifications

Table 71. Intas Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 72. Intas Pharmaceuticals Sales Value Proportion by Product in 2024

Table 73. Intas Pharmaceuticals Sales Value Proportion by Application in 2024

Table 74. Intas Pharmaceuticals Sales Value Proportion by Geographic Area in 2024

Table 75. Intas Pharmaceuticals Enzalutamide Soft Capsules SWOT Analysis

Table 76. Intas Pharmaceuticals Recent Developments

Table 77. Aprazer Healthcare Pharma Corporation Information

Table 78. Aprazer Healthcare Pharma Description and Major Businesses

Table 79. Aprazer Healthcare Pharma Product Models, Descriptions and Specifications

Table 80. Aprazer Healthcare Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 81. Aprazer Healthcare Pharma Sales Value Proportion by Product in 2024

Table 82. Aprazer Healthcare Pharma Sales Value Proportion by Application in 2024

Table 83. Aprazer Healthcare Pharma Sales Value Proportion by Geographic Area in 2024

Table 84. Aprazer Healthcare Pharma Enzalutamide Soft Capsules SWOT Analysis

Table 85. Aprazer Healthcare Pharma Recent Developments

Table 86. Arechar Healthcare Corporation Information

Table 87. Arechar Healthcare Description and Major Businesses

Table 88. Arechar Healthcare Product Models, Descriptions and Specifications

Table 89. Arechar Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Arechar Healthcare Sales Value Proportion by Product in 2024

Table 91. Arechar Healthcare Sales Value Proportion by Application in 2024

Table 92. Arechar Healthcare Sales Value Proportion by Geographic Area in 2024

Table 93. Arechar Healthcare Enzalutamide Soft Capsules SWOT Analysis

Table 94. Arechar Healthcare Recent Developments

Table 95. Glenmark Pharma Corporation Information

Table 96. Glenmark Pharma Description and Major Businesses

Table 97. Glenmark Pharma Product Models, Descriptions and Specifications

Table 98. Glenmark Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 99. Glenmark Pharma Recent Developments

Table 100. BDR Pharma Corporation Information

Table 101. BDR Pharma Description and Major Businesses

Table 102. BDR Pharma Product Models, Descriptions and Specifications

Table 103. BDR Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 104. BDR Pharma Recent Developments

Table 105. Qilu Pharmaceutical Corporation Information

Table 106. Qilu Pharmaceutical Description and Major Businesses

Table 107. Qilu Pharmaceutical Product Models, Descriptions and Specifications

Table 108. Qilu Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 109. Qilu Pharmaceutical Recent Developments

Table 110. Kelun Pharmaceutical Corporation Information

Table 111. Kelun Pharmaceutical Description and Major Businesses

Table 112. Kelun Pharmaceutical Product Models, Descriptions and Specifications

Table 113. Kelun Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 114. Kelun Pharmaceutical Recent Developments

Table 115. Yichang Humanwell Pharmaceutical Corporation Information

Table 116. Yichang Humanwell Pharmaceutical Description and Major Businesses

Table 117. Yichang Humanwell Pharmaceutical Product Models, Descriptions and Specifications

Table 118. Yichang Humanwell Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 119. Yichang Humanwell Pharmaceutical Recent Developments

Table 120. Jiangsu Hansoh Pharmaceutical Corporation Information

Table 121. Jiangsu Hansoh Pharmaceutical Description and Major Businesses

Table 122. Jiangsu Hansoh Pharmaceutical Product Models, Descriptions and Specifications

Table 123. Jiangsu Hansoh Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 124. Jiangsu Hansoh Pharmaceutical Recent Developments

Table 125. PuraCap Pharmaceuticals Corporation Information

Table 126. PuraCap Pharmaceuticals Description and Major Businesses

Table 127. PuraCap Pharmaceuticals Product Models, Descriptions and Specifications

Table 128. PuraCap Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 129. PuraCap Pharmaceuticals Recent Developments

Table 130. Shenyang Hongqi Pharmaceutical Corporation Information

Table 131. Shenyang Hongqi Pharmaceutical Description and Major Businesses

Table 132. Shenyang Hongqi Pharmaceutical Product Models, Descriptions and Specifications

Table 133. Shenyang Hongqi Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 134. Shenyang Hongqi Pharmaceutical Recent Developments

Table 135. Key Raw Materials Distribution

Table 136. Raw Materials Key Suppliers

Table 137. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 138. Milestones in Production Technology Evolution

Table 139. Distributors List

Table 140. Market Trends and Market Evolution

Table 141. Market Drivers and Opportunities

Table 142. Market Challenges, Risks, and Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

List of Figures

Figure 1. Enzalutamide Soft Capsules Product Picture

Figure 2. Global Enzalutamide Soft Capsules Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Original Drug Product Picture

Figure 4. Generic Drug Product Picture

Figure 5. Global Enzalutamide Soft Capsules Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Hospital and Clinic

Figure 7. Retail Pharmacies

Figure 8. Other

Figure 9. Enzalutamide Soft Capsules Report Years Considered

Figure 10. Global Enzalutamide Soft Capsules Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 12. Global Enzalutamide Soft Capsules Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Enzalutamide Soft Capsules Revenue Market Share by Region (2020-2031)

Figure 14. Global Enzalutamide Soft Capsules Sales (2020-2031) & (K Units)

Figure 15. Global Enzalutamide Soft Capsules Sales (CAGR) by Region (2020-2031) (K Units)

Figure 16. Global Enzalutamide Soft Capsules Sales Market Share by Region (2020-2031)

Figure 17. Top 5 and Top 10 Manufacturers Enzalutamide Soft Capsules Sales Volume Market Share in 2024

Figure 18. Global Enzalutamide Soft Capsules Revenue Market Share Ranking (2024)

Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 20. Original Drug Revenue Market Share by Manufacturer in 2024

Figure 21. Generic Drug Revenue Market Share by Manufacturer in 2024

Figure 22. Global Enzalutamide Soft Capsules Sales Market Share by Type (2020-2031)

Figure 23. Global Enzalutamide Soft Capsules Revenue Market Share by Type (2020-2031)

Figure 24. Global Enzalutamide Soft Capsules Sales Market Share by Application (2020-2031)

Figure 25. Global Enzalutamide Soft Capsules Revenue Market Share by Application (2020-2031)

Figure 26. North America Enzalutamide Soft Capsules Sales YoY (2020-2031) & (K Units)

Figure 27. North America Enzalutamide Soft Capsules Revenue YoY (2020-2031) & (US$ Million)

Figure 28. North America Top 5 Manufacturers Enzalutamide Soft Capsules Sales Revenue (US$ Million) in 2024

Figure 29. North America Enzalutamide Soft Capsules Sales Volume (K Units) by Type (2020- 2031)

Figure 30. North America Enzalutamide Soft Capsules Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 31. North America Enzalutamide Soft Capsules Sales Volume (K Units) by Application (2020-2031)

Figure 32. North America Enzalutamide Soft Capsules Sales Revenue (US$ Million) by Application (2020-2031)

Figure 33. US Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 34. Canada Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 35. Mexico Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 36. Europe Enzalutamide Soft Capsules Sales YoY (2020-2031) & (K Units)

Figure 37. Europe Enzalutamide Soft Capsules Revenue YoY (2020-2031) & (US$ Million)

Figure 38. Europe Top 5 Manufacturers Enzalutamide Soft Capsules Sales Revenue (US$ Million) in 2024

Figure 39. Europe Enzalutamide Soft Capsules Sales Volume (K Units) by Type (2020-2031)

Figure 40. Europe Enzalutamide Soft Capsules Sales Revenue (US$ Million) by Type (2020-2031)

Figure 41. Europe Enzalutamide Soft Capsules Sales Volume (K Units) by Application (2020-2031)

Figure 42. Europe Enzalutamide Soft Capsules Sales Revenue (US$ Million) by Application (2020-2031)

Figure 43. Germany Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 44. France Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 45. U.K. Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 46. Italy Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 47. Russia Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 48. Asia-Pacific Enzalutamide Soft Capsules Sales YoY (2020-2031) & (K Units)

Figure 49. Asia-Pacific Enzalutamide Soft Capsules Revenue YoY (2020-2031) & (US$ Million)

Figure 50. Asia-Pacific Top 8 Manufacturers Enzalutamide Soft Capsules Sales Revenue (US$ Million) in 2024

Figure 51. Asia-Pacific Enzalutamide Soft Capsules Sales Volume (K Units) by Type (2020- 2031)

Figure 52. Asia-Pacific Enzalutamide Soft Capsules Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 53. Asia-Pacific Enzalutamide Soft Capsules Sales Volume (K Units) by Application (2020-2031)

Figure 54. Asia-Pacific Enzalutamide Soft Capsules Sales Revenue (US$ Million) by Application (2020-2031)

Figure 55. Indonesia Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 56. Japan Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 57. South Korea Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 58. China Taiwan Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 59. India Enzalutamide Soft Capsules Revenue (2020-2031) & (US$ Million)

Figure 60. Central and South America Enzalutamide Soft Capsules Sales YoY (2020-2031) & (K Units)

Figure 61. Central and South America Enzalutamide Soft Capsules Revenue YoY (2020-2031) & (US$ Million)

Figure 62. Central and South America Top 5 Manufacturers Enzalutamide Soft Capsules Sales Revenue (US$ Million) in 2024

Figure 63. Central and South America Enzalutamide Soft Capsules Sales Volume (K Units) by Type (2021-2031)

Figure 64. Central and South America Enzalutamide Soft Capsules Sales Revenue (US$ Million) by Type (2020-2031)

Figure 65. Central and South America Enzalutamide Soft Capsules Sales Volume (K Units) by Application (2020-2031)

Figure 66. Central and South America Enzalutamide Soft Capsules Sales Revenue (US$ Million) by Application (2020-2031)

Figure 67. Brazil Enzalutamide Soft Capsules Revenue (2020-2025) & (US$ Million)

Figure 68. Argentina Enzalutamide Soft Capsules Revenue (2020-2025) & (US$ Million)

Figure 69. Middle East, and Africa Enzalutamide Soft Capsules Sales YoY (2020-2031) & (K Units)

Figure 70. Middle East and Africa Enzalutamide Soft Capsules Revenue YoY (2020-2031) & (US$ Million)

Figure 71. Middle East and Africa Top 5 Manufacturers Enzalutamide Soft Capsules Sales Revenue (US$ Million) in 2024

Figure 72. Middle East and Africa Enzalutamide Soft Capsules Sales Volume (K Units) by Type (2021-2031)

Figure 73. South America Enzalutamide Soft Capsules Sales Revenue (US$ Million) by Type (2020-2031)

Figure 74. Middle East and Africa Enzalutamide Soft Capsules Sales Volume (K Units) by Application (2020-2031)

Figure 75. Middle East and Africa Enzalutamide Soft Capsules Sales Revenue (US$ Million) by Application (2020-2031)

Figure 76. GCC Countries Enzalutamide Soft Capsules Revenue (2020-2025) & (US$ Million)

Figure 77. Turkey Enzalutamide Soft Capsules Revenue (2020-2025) & (US$ Million)

Figure 78. Egypt Enzalutamide Soft Capsules Revenue (2020-2025) & (US$ Million)

Figure 79. South Africa Enzalutamide Soft Capsules Revenue (2020-2025) & (US$ Million)

Figure 80. Enzalutamide Soft Capsules Industry Chain Mapping

Figure 81. Regional Enzalutamide Soft Capsules Manufacturing Base Distribution (%)

Figure 82. Global Enzalutamide Soft Capsules Production Market Share by Region (2020-2031)

Figure 83. Enzalutamide Soft Capsules Production Process

Figure 84. Regional Enzalutamide Soft Capsules Production Cost Structure

Figure 85. Channels of Distribution (Direct Vs Distribution)

Figure 86. Bottom-up and Top-down Approaches for This Report

Figure 87. Data Triangulation

Figure 88. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Organic Zinc Supplements Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-38U19850

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Egg Protein Hydrolysates Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-0Z20517

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global PAC Flocculant Dosing Device Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28R19905

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Polyaspartic Acid Magnesium Salt(PASP-Mg) Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-17G20275

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions